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Abstract
Background: In Guadeloupe and Martinique, two French Overseas Departments, colorectal cancer (CRC) has
become an essential public health issue. However, little is known about CRC characteristics and the p53 status in
these populations, particularly in Guadeloupe, whereas certification of a cancer registry has been recently validated.
Methods: This was a descriptive retrospective study of 201 patients who, between 1995 and 2000, underwent
surgery for CRC in the Guadeloupe Teaching Hospital (GlpeTH; 83 patients) and in the Martinique Teaching Hospital
(MqueTH; 118 patients). The clinicopathological features and the p53 expression, evaluated with
immunohistochemistry, were compared at the time of diagnosis. A relationship between these parameters and the
p53 expression was also studied. Data were analysed, using the SPSS computer software version 17.0.
Results: No statistical difference was found between the two groups of patients regarding age (p = 0.60),
percentage of young patients (≤50 years; p = 0.94)), sex (p = 0.47), histological type (p = 0.073) and tumour sites
(p = 0.65), although the GlpeTH patients were diagnosed with more distal colon cancers (54.2%) than the Mque TH
patients (47.4%). By contrast, a significant difference was found regarding the tumour grade (p < 0.0001), the pTNM
stage (p = 0.045) and the pT stage (p < 0.0001). Regarding p53 expression, solely for the MqueTH patients, nuclear
expression was associated with pTNM, the percentage of p53 negative tumours increasing with the progression of
the pTNM stages (p = 0.029).
Conclusions: For the first time, this study reveals discrepancies in clinicopathological features and in the p53 status
between the two groups of patients. The GlpeTH patients were diagnosed with more moderated CRCs but with
few CRCs at pTNM IV stage. By contrast, the MqueTH patients were diagnosed with more differentiated tumours,
but with many more CRCs at pTNM IV stage. This paradox may be due to differences in tumour location (distal vs
proximal), multiplicity of the genetic profiles of patients, or patients getting treatment elsewhere. Although our
study is limited due to its small size, it emphasizes the originality of our results.
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Background
Colorectal cancer is a major cause of morbidity and mor-
tality in men and women worldwide [1,2]. Incidence in
France is comparable to the one found in other high-risk
areas like Western Europe, North America, Australia/New
Zealand and Japan [2], Africa and Asia being lower-risk
areas [1]. Despite considerable efforts made for the last
decades, CRC remains one of the most frequent, deadly
cancers triggered by environmental and genetic factors
[3]. CRC develops through a series of progressive changes
defined by clinical and histopathological parameters [3,4].
Genetic changes, including inactivation of the tumour
suppressor gene p53, have been often associated with the
different steps of neoplastic progression in CRC [5-7]. The
p53-suppressor gene is the most frequently mutated gene
identified in solid human malignancy [6]. Mutation of the
p53 gene results in the production of a protein with
altered growth regulatory properties and with a conform-
ational change [7-9]. The latter feature prolongs its life-
span, stability and accumulation, enabling p53 detection
with routine immunohistochemistry (IHC) [9,10].
Colorectal cancer in Guadeloupe and Martinique, two
French overseas regions in the Caribbean, with a similar
health care system, a similar medical practice as well as a
similar socio-economic status, is the second most common
cancer in men and the third in women, becoming an im-
portant public health problem. The incidence of CRC has
increased five-fold in 25 years. The main factors for this in-
crease are not known, but may be due to changes in dietary
habits, and/or to environmental exposures. For example, in
1995, twenty-five and thirty-seven cases of CRC were diag-
nosed in the GlpeTH and in the MqueTH, respectively. In
2008, 138 cases were diagnosed in Guadeloupe, versus 189
cases in Martinique [11]. Nevertheless, there are little data
regarding the patterns of CRC, particularly in Guadeloupe.
As far as we know, there are only three studies which have
been published on this topic: one of Serra et al. [12] on the
comparison of cancer morbidity between Guadeloupe,
Martinique and French metropolitan regions; one of
Ngasseu et al. [13] on CRC incidence and mortality
rates in Martinique, and, finally, the study of Dieye et al.
[14] on epidemiological cancer transition in Martinique.
The purpose of this retrospective study was to describe
the clinicopathological characteristics of CRC in patients
who, between 1995 and 2000, underwent surgery in the
GpleTH and in the MqueTH. In addition, the p53 pro-
tein expression being not known, we also studied its pat-
tern of expression and we determined its association
with the clinicopathological parameters analysed.
Methods
Patient information and tissue samples
This descriptive retrospective study was approved by the
local Ethical committee of both teaching hospitals. In the
GlpeTH, 121 patients were seen for CRC between 1995
and 2000. Twelve patients (9.9%) were lost to follow up
and 109 patients underwent surgery. Out of the 109 pa-
tients, 24 who only had biopsies were excluded, as well as
2 who did not have complete clinical data. Finally, 83 pa-
tients were eligible. In the MqueTH, a total of 118 patients
were eligible, 4 being excluded for absence of clinical data.
Archival formalin-fixed and paraffin-embedded tumour
tissues and normal mucosa, taken 5 cm away from the
tumour area, were available for a total of 201 CRCs. None
of the patient had received chemotherapy or radiotherapy
prior surgical resection. Two pathologists (MO, AM) indi-
vidually reviewed all the haematoxylin/eosin stained slides.
Histological type, tumour grade and tumour stage were
determined according to the WHO and TNM classifica-
tion systems. Regarding cancer location, the cases were
grouped either into 4 categories: right colon, left colon,
sigmoid colon and rectum, or three categories: proximal
colon (right and transverse), distal colon (left and sigmoid)
and rectum, when appropriate [4].
There are at least three reasons why we selected the
1995–2000 period: Firstly, in 1995, one could notice that
the percentage of black people descending from deporta-
tions of Africans as slaves has evolved, leading to dispar-
ities between Martinique and Guadeloupe [15]. Indeed,
the percentage of mixed raced population was greater in
the former (91%) than in the latter (86%); inversely, the
percentage of black people was lower in Martinique
(6.2%) than in Guadeloupe (11.6%). Secondly, from 1995
on, a significant increase in CRC incidence, strengthened
by the clinicians of the Department of Medical informa-
tion of the GlpeTH, could be observed, whereas the
French National Commission of Data Processing and Civil
Liberty (CNIL) has recently authorized the establishment
of a cancer registry for Guadeloupe. Thirdly, data from
the MqueTH patients were available for the same period
of time (1995–2000), which makes the comparison be-
tween the GlpeTH and MqueTH patients easier, as the
two French overseas regions have a similar health care
system and similar medical practices.
Immunohistochemical detection of p53 and staining
evaluation
For immunohistochemistry (IHC) all the slides were treated
in the department of anatomopathology of MqueTH to
avoid discrepancy. Four-μm sections obtained from the
archival paraffin embedded tissues (tumour and normal
adjacent) were deparaffinised using toluene and a graded
series of ethanol. After rehydration, endogenous peroxidase
activity was blocked with 3% hydrogen peroxide in absolute
methanol and then, microwave antigen retrieval was
performed in a 10 mM citrate buffer for 30 minutes at
high power before antibody labelling. The immunohis-
tochemical procedure was performed with a Ventana
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auto-immunohistochemical stainer (Illkirch, France) ac-
cording to the manufacturer’s guidelines. The mouse
monoclonal antibody (clone DO-1; IgG2a; Immunotech,
Marseille, France), which recognises both wild-type and
mutant forms of human p53 protein, was used at a dilution
of 1:50. Primary antibody was omitted in the negative con-
trol. The antigen-antibody complex was visualized using
the Ventana/View detection kit for biotin streptavidin-
horseradish-peroxydase. Slides were counterstained with
haematoxylin before mounting. The positive reaction,
shown by a brown colour, was evaluated under a light
microscope both at a low and a high power and was
scored by two pathologists (MO, AM) who were blinded
to the origin of the sections and to the clinicopathologi-
cal features of the patients. Compared with the negative
control and/or the adjacent normal mucosa, p53 stain-
ing was considered as positive when the tumour cell
nuclei were stained, irrespective of the percentage of posi-
tive cells; the staining was scored on semi-quantitative
scales as follows: no reaction (0), weak reaction (+), mod-
erate reaction (++) and strong reaction (+++). In the cases
where there was initial disagreement, a consensus was ob-
tained after discussion. Finally, 76 slides from the GlpeTH
and 117 slides from the MqueTH, were analysed.
Statistical analyses
Statistical analyses were performed using the Statistical
Package for the Social Science (SPSS) computer software
version 17.0 (IBM SPSS Statistics, Chicago, IL, USA).
The Chi-square test or Fisher’s exact test was used when
appropriate, for comparing categorical variables (contin-
gency tables). The Student t test was used to compare
differences between quantitative variables. Various typical
prognostic factors were considered for univariate analysis.
Multivariate analysis (logistic regression) was performed
for adjusting p53 group overexpression (negative p53
versus positive p53) with clinicopathological parame-
ters. A p value less than 0.05 was considered statistically
significant.
Results
Description of patients according to clinical and
pathological features
The results are summarized in Table 1. Among the 83
GlpeTH patients included in the study, 51.8% were males
and 48.2% were females with a mean age of 69.0 years
(ranging from 34 to 99 years old). Most of the patients
were more than 50 years-old (84.3%), whereas those who
were less than 50-years old represented 15.7%. The sig-
moid colon was the most common site of tumour (36.1%),
the rectum representing 12.0%. When the tumour site was
divided into the proximal and the distal colons, the
GlpeTH patients were found to be diagnosed with more
distal colon cancers (54.2%) than proximal colon cancers
(33.8%) (Table 1). Considering the morphological aspect
of the tumour cells and how the latter were organised,
and the comparison with the normal adjacent mucosa
(Figure 1A), the GlpeTH patients were diagnosed with
well (Figure 1B; 41.5%), moderate (Figure 1C; 53.2%)
and poorly differentiated CRCs (Figure 1D; 5.3%). TNM
stage II (60.2%) and pT3 stage (62.6%) were the most
common stages.
Among the 118 MqueTH patients included in the study
(Table 1), 53.4% were females and 46.6% were males with
Table 1 Patient characteristics: comparison GlpeTH and
MqueTH
GlpeTH MqueTH p value
n = 83 (%) n = 118 (%)
Mean age 69.0 67.9 0.60(a)
Range 34 - 99 24 - 96
Age 0.94(b)
≤ 50 years 13 (15.7) 18 (15.3)
> 50 years 70 (84.3) 100 (84.7)
Sex
Male 43 (51.8) 55 (46.6) 0.47(b)
Female 40 (48.2) 63 (53.4)
Histological type 0.073(c)
Adenocarcinoma 77 (96.4) 98 (83.0)
Mucinous adenocarcinoma 5 (2.4) 11 (9.3)
Undifferentiated carcinoma 1 (1.2) 9 (7.7)
Tumour sites 0.65(c)
Right colon 25 (30.1) 34 (28.8)
Left colon 15 (18.1) 17 (14.4)
Transverse colon 3 (3.7) 9 (7.7)
Sigmoid colon 30 (36.1) 39 (33.0)
Rectum 10 (12.0) 19 (16.1)
Tumour grade <0.0001(c)
Well differentiated 32 (41.5) 83 (84.7)
Moderately differentiated 41 (53.2) 12 (12.2)
Poorly differentiated 4 (5.3) 3 (3.1)
pTNM 0.045(c)
0 /I 5 (6.0) 11 (9.3)
II 50 (60.2) 57 (48.3)
III 27 (32.5) 38 (32.2)
IV 1 (1.2) 12 (10.2)
pT stage <0.0001(c)
T0-T2 12 (14.5) 30 (25.2)
T3 52 (62.6) 31 (26.5)
T4 19 (22.9) 57 (48.3)
Data are given as number and percentage (in brackets) based on the total
number of cases in GlpeTH and MqueTH. (a)Student t test. (b)Fisher’s exact test.
(c)Chi-square test.
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a median age of 67.9 years (ranging from 24 to 96 years
old). Interestingly also, 15.3% of the patients were less
than 50 years old. Sigmoid colon was also the most com-
mon site of tumour (33.0%), rectum representing 16.1%.
Approximately, equivalent percentages of distal colon can-
cers (47.4%) and proximal colon cancers (36.5%) were
diagnosed. The latter was often found associated with
greater aggressiveness [16]. Regarding the tumour grade,
84.7% of the CRC cases were well differentiated, 12.2%
moderately differentiated, and 3.1% poorly differentiated
(Figure 1 and Table 1). pT4 stage (48.3%) was the most
common stage (Table 1). Thus, the higher percentages of
patients diagnosed with mucinous adenocarcinomas, well
differentiated CRCs and pTNM stage IV CRCs were seen
in the MqueTH as compared with the GlpeTH.
p53 immunohistochemical analyses
Pattern of expression
Figures 2 and 3 show the results obtained for the p53
staining. We did not find any staining in the adjacent
normal mucosa (Figure 2A). p53 staining was specific to
tumour cells and was detected exclusively in the nuclei
(Figure 2B) compared with the negative control (Figure 2C).
Among the 76 CRCs detected in the GlpeTH, 32 cases
(42.1%) were p53 negative and 44 cases (57.8) p53 positive.
Among the positive cases, 16.0% were weakly stained (+),
28.0% were moderately stained (++) and 14.0% were
strongly stained (+++) (Figure 3). In the MqueTH, p53 was
negative in 34.2% (40/117) of the CRCs and positive in
65.8% (77/117). Among the positive cases, 32.0% were
weakly stained, 26.0% were moderately stained, and 8.0%
were strongly stained (Figure 3). Thus, strong nuclear p53
positive tumours (+++) were more frequent in GlpeTH
CRCs (14.5%) than in MqueTH CRCs (8.5%) although, this
difference did not reach statistical significance (p = 0.069).
Association with clinicopathological features
We further analysed the relationship between the p53
nuclear accumulation and the clinicopathological vari-
ables studied above. In the case of the GlpeTH patients,
there was no significant association between the p53 accu-
mulation and any of the pathological variables, although
Figure 1 Histopathological characteristics of colon cancer tissue as compared with normal mucosa. Representative micrographs of
formalin-fixed and paraffin-embedded tissues counterstained with hematoxylin and eosin. (A) Normal tissue taken 5-cm away from the tumour
area (× 10); (B) well differentiated tumour (× 10); (C) moderately differentiated tumour (× 20). D: poorly differentiated tumour (× 20).
Figure 2 Immunohistochemical staining pattern of p53. (A) Normal adjacent tissue (× 20); (B) high positive staining detecting in the nucleus
of the tumour cells (× 10); (C) negative control without the primary antibody (× 20).
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cancers localised on the distal colon tended to be more
frequently p53 positive (61.4%) than cancers localised on
the proximal colon (31.8%) (Table 2; p = 0.73). Likewise,
CRC diagnosed at early pTNM stage had a greater ten-
dency to be p53 positive (65.9%) than CRC diagnosed at
late pTNM stage (34.1%) (Table 2; p = 0.92).
In the case of the MqueTH patients, approximately
equivalent percentages of tumour localised on the distal
and proximal colons were found to be nuclear p53 posi-
tive (Table 2; 42.8% vs 35.3%; p = 0.64). Interestingly
however, a significant association between p53 nuclear
accumulation and the pTNM stage was observed in the
latter patients (p = 0.029), indicating that the proportion
of CRC negative for nuclear p53 increased with progres-
sion of the CRC stages (Table 2).
Finally, the overall patient population (GlpeTH and
MqueTH: 193 patients) was studied (Table 3). No signifi-
cant association between the p53 expression and any of
the pathological variables analysed was found, except for
tumour site. Indeed, either in univariate analysis (Table 3;
p = 0.026) or multivariate logistic regression analysis
(Table 4; OR = 1.89; 95% CI = 1.03-3.46; p = 0.039), the
patients whose tumours were diagnosed either on sig-
moid colon or rectum were 1.89 times more likely to be
positive for p53 nuclear accumulation than if the tumours
were diagnosed on colon (left, right and transverse).
Discussion
Our data indicate disparities between the GlpeTH and
the MqueTH patients regarding CRC cartography. To our
knowledge, no other study has investigated and compared
the clinicopathological features and the p53 pattern of
expression of CRC in these populations.
There were no differences in age (p = 0.94), sex (p =
0.47), histology (p = 0.073) and tumour sites (p = 0.65)
between CRCs in the GlpeTH and the MqueTH patients,
although the percentage of men was slightly higher in
the former patients (51.8%) than in the latter patients
(46.6%) and, inversely the percentage of women was
slightly lower (48.2% vs 53.4%). Approximately equiva-
lent percentages of proximal colon (36.5%) and distal
colon cancers (47.4%) were diagnosed in the MqueTH
patients as compared with the high proportion of distal
colon cancers diagnosed in the GlpeTH patients (54.2%).
In accordance with this latter result, Dieye et al. [11] re-
port that, among the 138 Guadeloupian patients re-
cruited in 2008 (cancer registry data), 58.9% were males
and 41.1% females, and that distal colon cancers were
more frequent. Also, the data of Dieye et al. [11,14] and
Ngasseu et al. [13] confirm our results obtained with the
MqueTH patients.
Our non-standardized results were also compared
with those obtained for patients in Metropolitan France
[11,17,18] and for Caucasian patients [1,2,4]. The pro-
portion of colon cancer cases occurring before the age
of 50 was found to be higher in the French departments
(15% vs 2-6%), whereas the proportion of rectal cancer was




Figure 3 p53 staining analysis using a scoring method based
on nuclear staining intensity. (0) negative staining, (1) weak
staining, (2) moderate staining, (3) strong staining.
Table 2 Association of p53 with tumour site and pTNM in each Teaching Hospital
Parameters GlpeTH n = 76 MqueTH n = 117
p53 positve p53 negative p P53 positive P53 negative p
n (%) n (%) n (%) n (%)
Tumour site 0.73(c) 0.64(c)
Proximal colon 14 (31.8) 13 (40.6) 27 (35.3) 17 (42.5)
Distal colon 27 (61.4) 17 (53.5) 37 (48.0) 17 (42.5)
Rectum 3 (6.8) 2 (5.9) 13 (16.9) 6 (15.0)
pTNM 0.92(c) 0.029(c)
0-I 2 (4.5) 2 (6.2) 4 (5.2) 7 (17.5)
II 27 (61.4) 20 (62.5) 43 (55.8) 14 (35.0)
III - IV 15 (34.1) 10 (31.3) 30 (39.0) 19 (47.5)
Data are given as number and percentage (in brackets) based on the total number of positive cases in GlpeTH and in MqueTH. (c)Chi-square test.
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compared with the Caucasian patients, African Americans
are typically diagnosed with CRC at a younger age, with a
higher incidence of tumours located on the proximal colon
and with well-differentiated CRC [19-23]. Tanzanian pa-
tients (African) are diagnosed at a young age as well, how-
ever, moderately differentiated and rectosigmoid tumours
in those patients were mostly represented [24].
Histopathological data was further discussed. Significant
differences were found between the MqueTH and the
GlpeTH patients regarding tumour grade (p < 0.0001), con-
sidered as an independent prognostic factor [4], tumour
stage (p = 0.045) and depth of tumour invasion (p < 0.0001).
Moderately (53.2%) and poorly differentiated CRCs (5.3%)
were diagnosed in the GlpeTH patients, whereas CRCs
were at early pTNM stages (66.2%). By contrast, well
differentiated CRCs (84.7%) were more frequently diag-
nosed in the MqueTH patients, whereas pTNM stage IV
CRCs were highly represented (10.2%). As a reminder,
the value obtained for African American and Caucasian
patients was 14% and for Metropolitan France patients
it was 13-22% [17-22].
As far as p53, the “guardian of the genome”, is con-
cerned [25], reviews of the literature indicate that its
clinical significance in CRC is still raising a controversial
debate, probably due to the mode of patient selection,
the origin of patients, tumour sites or the use of differ-
ent p53 antibodies for IHC [6,26-32]. For example, the
study of Iacopetta [6] indicates that a high frequency of
p53 mutation was observed in distal colon and rectal
cancer; however, these alterations in the p53 gene are
likely to have very little or no prognostic significance in
CRC patients treated with surgery alone. This could be
the case for the GlpeTH and the MqueTH patients in-
cluded in the present study. On the other hand, the
study of Mane et al. [31] indicates that approximately
equivalent proportions of distal and proximal colon can-
cers were positive for p53 in African American patients,
whereas distal colon cancer from white patients were
more frequently positive for p53 than proximal colon
cancer was. The authors conclude that nuclear p53 was
a valuable indicator of poor prognosis only for white pa-
tients with tumours located on the proximal colon. Diez
et al. [32] show that p53 overexpression was more fre-
quent in distal than in proximal tumours, and the au-
thors concluded that p53 exhibited different prognostic
values in distal and proximal colon. Nevertheless, when
we used the monoclonal DO-1 p53 antibody to visualize
the p53 expression and location, our IHC analyses indi-
cated that p53 overexpression was observed in 57.9%
Table 3 Association of p53 expression with
clinicopathological parameters
Parameters GlpeTH and MqueTH
p53positve p53negative p value
n = 121 (%) n = 72 (%)
Mean age 67.2 70.8 0.10(a)
Range 24 - 99 31 - 93
Age 0.68(b)
≤ 50 years 20 (16.5) 10 (13.9)
> 50 years 101 (83.5) 62 (86.1)
Sex 1.0(b)
Male 60 (49.6) 35 (48.6)
Female 61 (50.4) 37 (51.4)
Histologycal type 0.38(c)
ADK 110 (90.9) 61 (84.7)
Mucinous ADK 8 (6.6) 7 (9.7)
Other 3 (2.5) 4 (5.6)
Tumour site 0.072(c)
Colon* 55 (45.5) 45 (62.5)
sigmoid 46 (38.0) 19 (26.4)
Rectum 20 (16.5) 8 (11.1)
Tumour site 0.026(b)
Colon* yes 55 (45.5) 45 (62.5)
Colon no 66 (54.5) 27 (37.5)
pTNM 0.11(c)
0-I 6 (5.0) 9 (12.5)
II 70 (57.8) 34 (47.2)
III - IV 45 (37.2) 29 (40.3)
Teaching Hospital 0.29(b)
Guadeloupe 44 (37.7) 32 (43.1)
Martinique 77 (62.3) 40 (56.9)
ADK: adenocarcinoma. Data are given as number and percentage (round
brackets) based on the total number of p53 positive and p53 negative cases in
GlpeTH and MqueTH. (a)Student t test. (b)Fisher’s exact test. (c)Chi-square test.
*right, left and transverse.
Table 4 Multivariate logistic regression analysis
OR CI 95% P value
Age 0.987 0.967 - 1.007 0.20
Sex 0.80
Female 1.079 0.592 - 1.976
Male
Tumour site 0.039
Colon* yes 1.891 1.033 - 3.463
Colon no
pTNM 0.38
0,I,II or III 1.831 0.471 - 7.118
IV
Teaching Hospital 0.37
Guadeloupe 1.324 0.715 - 2.449
Martinique
*right, left and transverse.
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and 65.8% of the CRCs of the GlpeTH and the MqueTH
patients, respectively, which is in accordance with the 40-
81% range of p53 positivity observed in previous reports
[9,10,27-32]. Staining was restricted to the nuclei of malig-
nant cells. Regarding the GlpeTH patients, 61.4% of the
distal colon cancers were p53 positive, versus 31.8% of the
proximal colon cancers. Regarding the MqueTH patients,
equivalent proportions of the distal and the proximal
colon cancers were positive for p53. The paradox noticed
for the clinical, pathological data was also found for the
p53 staining pattern. Indeed, the MqueTH data were, in
part, close to those observed for African Americans, al-
though the Martinican population is highly mixed [15].
Conclusions
This retrospective, descriptive, comparative study has en-
abled us to map the clinicopathological characteristics of
CRC in two groups of patients. The GlpeTH patients were
diagnosed with more moderated CRCs, a high percentage
of distal colon cancers, among which 61.4% were p53
positive, but with few pTNM IV stages. By contrast, the
MqueTH patients were diagnosed with more differenti-
ated tumours, equivalent percentages of proximal and dis-
tal colon cancers which were found equally positive for
p53, but with many pTNM IV stages. This paradox may
be due to differences in tumour location (distal vs prox-
imal), a multiplicity of genetic profiles of patients, or pa-
tients who were not treated locally. Even if our study is
limited due to its small size, it emphasizes the originality
of our results and should alert the physicians of the
GlpeTH and the MqueTH regarding patient management.
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